Species distribution and susceptibility profiles of Candida species isolated from vulvovaginal candidiasis, emergence of C. lusitaniae

Publish Year: 1398
نوع سند: مقاله ژورنالی
زبان: English
View: 62

This Paper With 9 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_CUMM-5-4_005

تاریخ نمایه سازی: 11 آذر 1402

Abstract:

Background and Purpose: The aim of the current study was to investigate the epidemiology of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), as well as the antifungal susceptibility patterns of Candida species isolates. Materials and Methods: A cross-sectional study was carried out on ۲۶۰ women suspected of VVC from February ۲۰۱۷ to January ۲۰۱۸. In order to identify Candida species isolated from the genital tracts, the isolates were subjected to polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) using enzymes Msp I and sequencing. Moreover, antifungal susceptibility testing was performed according to the Clinical and Laboratory Standards Institute guidelines (M۲۷-A۳). Results: Out of ۲۵۰ subjects, ۷۵ (۲۸.۸%) patients were affected by VVC, out of whom ۱۵ (۲۰%) cases had RVVC. Among the Candida species, C. albicans was the most common species (۴۲/۹۵; ۴۴.۲۱%), followed by C. lusitaniae (۱۸/۹۵; ۱۸.۹۵%), C. parapsilosis (۱۳/۹۵; ۱۳.۶۹%),  C. glabrata (۸/۹۵; ۸.۴۲%), C. kefyr (۶/۹۵; ۶.۳۱%), C. famata (۵/۹۵; ۵.۲۶%), C. africana (۲/۹۵; ۲.۱۱%), and C. orthopsilosis (۱/۹۵; ۱.۰۵%), respectively. Multiple Candida species were observed in ۲۸% (۲۱/۷۵) of the patients. Nystatin showed the narrowest range of minimum inhibitory concentration (MIC) (۰.۲۵-۱۶ μg/ml) against all Candida strains, whereas fluconazole (۰.۰۶۳-۶۴ μg/ml) demonstrated the widest MIC range. In the current study, C. lusitaniae, as the second most common causative agent of VVC, was susceptible to all antifungal agents. Furthermore, ۶۱.۱% of C. lusitaniae isolates were inhibited at a concentration of ≤ ۲ μg/ml, while۳۸.۹% (n=۷)of them exhibited fluconazole MICs above the epidemiologic cutoff values (ECV). Candida species showed the highest overall resistance against fluconazole (۶۱.۳%), followed by itraconazole (۴۵.۲%) and caspofungin (۲۳.۷%). All of C. albicans strains were resistant to itraconazole with a MIC value of ≥ ۱ μg/ml; in addition, ۸۷.۵% of them were resistant to fluconazole. Moreover, ۱۰۰% and ۸۷.۵% of C. glabrata strains were resistant to caspofungin and fluconazole, respectively. Conclusion: As the findings revealed, the majority of VVC cases were caused by non-albicans Candida species which were often more resistant to antifungal agents. Candida lusitaniae generally had fluconazole MICs above the ECV. Given the propensity of C. lusitaniae to develop resistance under drug pressure, antifungals should be administered with caution. The emergence of these species justify the epidemiological surveillance surveys to watch out the distribution of yeast species.

Authors

Seyedebrahim Hashemi

Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

Tahereh Shokohi

Invasive Fungi Research Centre (IFRC), Mazandaran University of Medical Sciences, Sari, Iran

Mahdi Abastabar

Invasive Fungi Research Centre (IFRC), Mazandaran University of Medical Sciences, Sari, Iran

Narges Aslani

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Mahbobeh Ghadamzadeh

Gynecology and Obstetrics Department of Hazrat-e- Zainab Hospital, Babolsar, Iran.

Iman Haghani

Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, ...
  • Alizadeh M, Kolecka A, Boekhout T, Zarrinfar H, Ghanbari Nahzag ...
  • Vandeven AM, Emans S. Vulvovaginitis in the child and adolescent. ...
  • Minooeianhaghighi MH, Sehatpour M, Shokri H. Determination of drug susceptibility ...
  • Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, ...
  • Malazy OT, Shariat M, Heshmat R, Majlesi F, Alimohammadian M, ...
  • Noori M, Dakhili M, Sepahvand A, Davari N. Evaluation of ...
  • Nazeri M, Mesdaghinia E, Moravej SA, Atabakhshiyan R, Soleymani F. ...
  • Dovnik A, Golle A, Novak D, Arko D, Takac I. ...
  • Khanmohamadi M, Mehbod AS, Noraeepour M, Didehdar M. Molecular identification ...
  • Fornari G, Vicente VA, Gomes RR, Muro MD, Pinheiro RL, ...
  • Favel A, Michel-Nguyen A, Peyron F, Martin C, Thomachot L, ...
  • Asner SA, Giulieri S, Diezi M, Marchetti O, Sanglard D. ...
  • Khosravi Rad K, Falahati M, Roudbary M, Farahyar S, Nami ...
  • Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, ...
  • Walker PP, Reynolds MT, Ashbee HR, Brown C, Evans EG. ...
  • Rex JH, Rinaldi M, Pfaller M. Resistance of Candida species ...
  • Sharifynia S, Falahati M, Akhlaghi L, Foroumadi A, Fateh R. ...
  • Didehdar M, Khansarinejad B, Amirrajab N, Shokohi T. Development of ...
  • Shokohi T, Soteh MH, Pouri ZS, Hedayati M, Mayahi S. ...
  • Romeo O, Criseo G. First molecular method for discriminating between ...
  • Abastabar M, Hosseinpoor S, Hedayati MT, Shokohi T, Valadan R, ...
  • Rex JH, Alexander BD, Andes D, Arthington-Skaggs B, Brown SD, ...
  • Santos ER, Dal Forno CF, Hernandez MG, Kubiça TF, Venturini ...
  • Abbasi Nejat Z, Farahyar S, Falahati M, Khozani M, Hosseini ...
  • Diba K, Namaki A, Ayatolahi H, Hanifian H. Comparison of ...
  • ۲۰۱۴; ۸(۳):۴۵-۵۰ ...
  • Hedayati MT, Taheri Z, Galinimoghadam T, Aghili SR, Yazdani Cherati ...
  • Mukasa KJ, Herbert I, Daniel A, Sserunkuma KL, Joel B, ...
  • Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida ...
  • Meyer SA, Payne RW, Yarrow D. Candida berkhout. The yeasts. ...
  • Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in ...
  • Blinkhorn RJ, Adelstein D, Spagnuolo PJ. Emergence of a newopportunistic ...
  • Hawkins JL, Baddour LM. Candida lusitaniae infections in the era ...
  • Minari A, Hachem R, Raad I. Candida lusitaniae: a cause ...
  • Reedy JL, Floyd AM, Heitman J. Mechanistic plasticity of sexual ...
  • Pappagianis D, Collins MS, Hector R, Remington J. Development of ...
  • Zhang J, Silao FG, Bigol UG, Bungay AA, Nicolas MG, ...
  • Baker JG, Nadler HL, Forgacs P, Kurtz SR. Candida lusitaniae: ...
  • Desnos-Ollivier M, Moquet O, Chouaki T, Guerin AM, Dromer F. ...
  • Merz WG. Candida lusitaniae: frequency of recovery, colonization, infection, and ...
  • Diba K, Makhdoomi K, Nasri E, Vaezi A, Javidnia J, ...
  • Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent ...
  • Khan Z, Ahmad S, Al-Sweih N, Khan S, Joseph L. ...
  • Florent M, Noël T, Ruprich-Robert G, Da Silva B, Fitton-Ouhabi ...
  • Shen XX, Zhou X, Kominek J, Kurtzman CP, Hittinger CT, ...
  • Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of ...
  • Lockhart SR, Pham CD, Kuykendall RJ, Bolden CB, Cleveland AA. ...
  • Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? ...
  • Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, ...
  • Espinel-Ingroff A, Turnidge J. The role of epidemiological cutoff values ...
  • Haleim M, El-Feky E, Sayed A, Kadry D, Mahmoud A, ...
  • Fattahi BA, Hoseinzadeh A, Jafari AA, Naghshi JM. Frequency distribution ...
  • Safdar A, Chaturvedi V, Cross EW, Park S, Bernard EM, ...
  • Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, ...
  • نمایش کامل مراجع